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CancerTo identify genomic markers with consistent effect on tumor dynamics across multiple cancer series, discrim-
ination indices based on proportional hazards models can be used since they do not depend heavily on the
sample size. However, the underlying assumption of proportionality of the hazards does not always hold, es-
pecially when the studied population is a mixture of cured and uncured patients, like in early-stage cancers.
We propose a novel index that quantiﬁes the capability of a genomic marker to separate uncured patients,
according to their time-to-event outcomes. It allows to identify genomic markers characterizing tumor
growth dynamic across multiple studies.
Simulation results show that our index performs better than classical indices based on the Cox model. It is
neither affected by the sample size nor the cure rate fraction.
In a cross-study of early-stage breast cancers, the index allows to select genomic markers with a potential
consistent effect on tumor growth dynamics.
© 2013 Elsevier Inc. All rights reserved.1. Introduction
Tumor growth is a complex process regulated by interplays of
genomic markers that either increase proliferation (oncogenes) or
decrease it (tumor suppressor genes). The identiﬁcation of genomic
markers with a consistent effect on tumor growth can be accelerated
by the combination of multiple cancer studies publicly available in
centralized databases. For such cross-study analyses, classical measures
of statistical signiﬁcance (such as p-values) are not well suited. They
have the drawback of confounding the effect size and the sample size.
Indeed, a weak association between a genomic marker and a disease
outcome can lead to signiﬁcant results from large sample size series,
whereas large effects can be considered as being not signiﬁcant from
small sample size series. However, researchers in translational genomic
medicine can gainmore valuable biological insights into the tumor pro-
cess from small sample size series with homogeneous selection or rare
tumor phenotypes, than from heterogeneous series with large sample
sizes or common tumor phenotypes. Thus, for cross-study analyses it
is of interest to consider a statistical criterion that quantiﬁes the ability
of a genomic marker to separate patient outcomes, without depending
heavily on the sample size.
For continuous outcome variables, such statistical criteria can be
obtained from the classical coefﬁcient of determination (noted as R2).).
rights reserved.This latter quantiﬁes the predictive ability of a variable to separate
subject outcomes. For censored time-to-event data, the extension of
this coefﬁcient is not straightforward and many options have been
proposed (referred to as pseudo-R2). In the context of the classical
Cox proportional hazards model [1], the proposed criteria are either
based on the proportion of randomness of the outcome given themark-
er [2] or on the proportion of randomness of the marker given the
outcome [3,4]. From a different perspective, we have introduced an
alternative criterion that can be interpreted in terms of the percentage
of separability between patients according to outcomes and markers
[5]. This set of criteria can be used for identifying factors having a prog-
nostic impact across a collection of heterogeneous genomic datasets of
various sizes but assume proportionality of the hazards over time. The
extension of these criteria in the case of non-proportional hazards
is challenging, as the parameter estimations require non-trivial algo-
rithms relying on complex likelihood derivations.
Departures from the classical Cox proportional hazards model are
frequently encountered in oncology. In particular, in early-stage cancer
studies, the population of patients is composed of individuals who
are either not susceptible (cured patients) or susceptible (uncured
patients) to experiencing a relapse after the primary treatment. For
the susceptible patients, the time to tumor relapse depends on the
tumor growth dynamic. This heterogeneity in the study population
leads to non-proportional hazards situations. The use of criteria based
on proportional hazards assumption may compromise any attempt to
identify markers linked to the tumor growth dynamic among uncured
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a novel discrimination index for selecting markers of tumor growth
dynamic across multiple cancer studies taking into account the cure
fraction.
The index quantiﬁes the capability of a genomic factor to separate
uncured patients according to their time-to-event outcome. It allows
to adjust for other covariates having a cure effect. Its properties can be
deduced from its link to the score statistic derived from the partial
likelihood under a cure rate model [6]. We show that this criterion
is bounded (ranging from zero to one), increases with the strength
of the marker effect, is not affected by the size of the fraction of
uncured patients and has a better discriminatory ability than criteria
based on proportional hazards model. The use of the index is illus-
trated on a cross-study analysis of a collection of publicly available
gene expression data of breast cancers.
2. Results
2.1. Simulations for evaluating the properties of the discrimination index
The objective of this section is to evaluate the behavior of the pro-
posed index denoted Id (see Material and methods) for different cure
fractions exp(−θ), values of parameter γ, values of parameter α, covar-
iate distributions, sample sizes n and percentages of censoring pc.
2.1.1. Simulation protocol
Survival timeswere generated according tomodel (1)withH(t) = t.
For a subject, we mimicked a genomic marker with either a discrete
distribution (Bernoulli ℬ(0.5)) or a continuous distribution (normal
N (0,1)). For mimicking a covariate acting on the cure proportion, we
considered a Bernoulli distributionℬ(0.5). Censoring times were inde-
pendently generated from a uniform distribution over [0,u]. Values for
u were computed from the chosen percentage of censoring and from
the parameters of the considered distributions. The percentage of censor-
ing below refers to the percentage of censored observations without the
cure fraction exp(−θ). The number of subjects was chosen to be equal
to 100, 200, and 500. The following conﬁgurations were considered:
cure fraction exp(−θ) = 0.3, 0.5, 0.7; percentage of censoring pc = 0%
or 25%; parameters eα = 1, 1.5, 2, 3, 4 and eγ = 1, 1.5, 2, 3, 4. For each
conﬁguration, 1000 replications were performed.
We compared the behavior of the proposed index to four classical
pseudo-R2 for censored data that can be interpreted in terms of
explained randomness and are linked to the Cox PH partial likelihood
function (see Additional File 1 for a detailed description). These indices
are the following: (i) Allison's index ρn2 [7], based on a transformation of
the partial log-likelihood ratio test; (ii) a modiﬁed version of Allison's
index ρk2 proposed by O'Quigley et al. [3]; (iii) Nagelkerke's index RN2
[8], which is amodiﬁcation of Allison's index dividing it by itsmaximum
value, and (iv) Xu andO'Quigley's index ρXOQ2 [4] based on a transforma-
tion of the Kullback–Leibler distance between the null and the alterna-
tive models.
2.1.2. Simulation results
Figs. 2 and 3 show the results of the simulations obtained with Id,
ρn2, RN2, ρk2 and ρXOQ2 for n = 200 subjects, exp(−θ) = 0.50, with one
confounding variable and G following a normal distribution. The
results for G ~ℬ(1/2) and for exp(−θ) = 0.30 and exp(−θ) = 0.70
are given in Additional File 2.
The different ﬁgures show that the value of Id increases with the
value of the strength of the effect of the genomic marker (through the
hazards ratio eγ). When γ = 0, the index is close to zero, and its value
increases when γ > 0. The four other indices do not have a stable
behavior regarding the genomic marker effect. In some cases, their
value remains close to zero whatever the value of γ. In other cases,
their value increases only for high hazard ratio values. For example,
when pc = 0 and G ~ℬ(1/2), the values of ρn2 and RN2 remain close tozero and the values of ρk2 and ρXOQ2 increase slightly but not enough to
reﬂect the increased effect of the genomic marker.
It is also important to note that our index is not affected by the
percentage of censoring pc, whereas the four other indices increase
with the percentage of censoring.
The comparison of Figs. 2, 3 and S1, S2 from Additional File 2 to Figs.
S3–S10 in the Additional File 2 show that our index is not affected by
changes in the cure fraction contrary to the four other indices.
Furthermore, the value of Id is not sensitive to the effect of covariate
acting on the cure fraction. In contrast, the values of ρn2, RN2, ρk2 and ρXOQ2 in-
crease as the value of parameter α increases.
Finally, Id is not affected by the sample size, but its variance decreases
when the sample size increases as expected (results not shown).2.2. Cross-study analysis of ﬁve breast cancer studies
The use of the proposed index is illustrated for a cross-study analysis
of a collection of ﬁve gene expression datasets of breast cancer patients.
For these early stage cancer patients, a non-negligible proportion of
them is cured after the primary treatment. In practice, the risk of failure
after ﬁve years is supposed to be negligible. Here, the objective is to
identify genomicmarkers having an impact on tumor growth dynamics
through disease progression of the uncured patients, for any primary
treatment (e.g. untreated, hormone therapy, chemotherapy) and
patient population (e.g. ER positive, ER negative).2.2.1. Breast cancer datasets
In this work, we considered ﬁve breast cancer gene expression
datasets that were publicly available from the GEO website (http://
www.ncbi.nlm.nih.gov/geo) and whose samples were hybridized using
the same microarray technology (Affymetrix, HU133A or HU133 Plus
2.0). For early stage breast tumors, it is commonly admitted that a
non-negligible fraction of patients is cured after the primary treatment.
The cure fraction varies between and within studies according to
clinico-pathological factors inﬂuencing the tumor burden. These factors
are used to adjust for the effect on the cure fraction.
For the ﬁve breast cancer studies, the hybridizations were per-
formed on the Affymetrix GeneChip HU133A, except for the GSE9195
and the GSE16446 cohorts, which were performed on HU133 Plus 2.0
(HU133A + HU133B). Thus, we restrained our analysis to the informa-
tion obtained from the 22,283 probe sets represented on the Affymetrix
GeneChip HU133A. The expression microarray data were standardized
and normalized using the robust multiarray average procedure [9].
We brieﬂy recalled the main characteristics of these studies. Fig. 4
shows Kaplan–Meier survival curves for the ﬁve series.
GSE11121 series [10]. This series is composed of 200 lymph node-
negative breast cancer patients who were not treated by systemic
therapy after surgery. Metastasis-free survival was deﬁned as the in-
terval from the date of the primary treatment to the date of the ﬁrst
occurrence of metastasis or last follow-up. The median metastasis-
free survival time was 149 months. The two years metastasis-free
survival was 92.9% [89.3%; 96.5%], and the ﬁve years metastasis-free
survival was 85.4% [80.6%; 90.6%]. The available clinico-pathological
factors were the histologic grade and the tumor size. Only the grade
(1–2 vs. 3) had a signiﬁcant impact on metastasis-free survival.
GSE12093 series [11]. This series is composed of 136 ER positive and
lymph node-negative breast cancer patients that were treated with
tamoxifen. The distant metastasis-free survival was deﬁned as the
interval from the date of the treatment to the date of the ﬁrst occur-
rence of metastasis or last follow-up. The median metastasis-free
survival time was 164 months. The two years metastasis-free sur-
vival was 97.1% [94.3%; 99.9%], and the ﬁve years metastasis-free
Fig. 1. Schematic representation of the notion of separabilty. Individuals who already failed are represented with an ‘x’. Individuals failing at the considered time are represented
with an ‘*’. Individuals who fail at a later time are represented by a ‘.’. Censored individuals are represented by a ‘c’. At times t5, t6 and t7, we can see the difference between the
weighted mean value of the genomic variable for the individuals who experience the event and those who are at risk but do not experience the event. The barplot represents
the change in the patient population: as times goes on, the fraction of uncured patients decreases and the fraction of cured patients increases.
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available for this series.
GSE16446 series [12–14]. This series is composed of 120 primary es-
trogen receptor (ER)-negative breast cancer patients who were treat-
ed with anthracycline (epirubicin) monotherapy. The metastasis-free
survival was deﬁned as the interval from the date of inclusion
to the ﬁrst occurrence of metastasis or last follow-up. The median
metastasis-free survival time was 60 months. The two years
metastasis-free survival was 81.9% [74.9%; 89.6%] and the ﬁve years
metastasis-free survival was 74.6% [65.2%; 85.3%]. Several clinico-
pathological factorswere available for 107 patients from this series in-
cluding the age, the histologic grade, the extent of the tumor (TNM
staging), the number of nodes (TNM staging), the ER (estrogen-
receptor) and the HER2 status. Only the local extent of the tumor
(T1–T2 vs. T3–T4) had a signiﬁcant impact on metastasis-free
survival.
GSE2034 series [15,16]. This series is composed of 286 lymph node-
negative breast cancer patients. Themetastasis-free survivalwas de-
ﬁned as the interval from the date of inclusion to the ﬁrst occurrence
of metastasis or last follow-up. The median metastasis-free survival
time was 80 months. The two years metastasis-free survival was
83.9% [79.8%; 88.3%] and the ﬁve years metastasis-free survival
was 66.7% [61.4%; 72.4%]. The ER status was measured but did not
have an impact on metastasis-free survival.
GSE9195 series [17,18]. This series is composed of 77 estrogen recep-
tor (ER)-positive breast tumor patients diagnosed with early stage
breast cancer and treated with adjuvant tamoxifen monotherapy.
The metastasis free survival was deﬁned as the time from the date
of inclusion to the ﬁrst occurrence of metastasis or last follow-up.
The median metastasis-free survival time was 47 months. The two
years metastasis-free survival was 97.4% [93.9%; 1000%], and the
ﬁve years metastasis-free survival was 86.9% [79.7%; 94.8%]. Five
clinico-pathological factors were measured. Age, progesterone statusand histological grade did not have a signiﬁcant effect on metastasis-
free survival, whereas the tumor size and lymph node status did.
The selection of genomic markers of tumor dynamics common to
these ﬁve studies was done in two steps (see Fig. 5). First, we calculated
the value of Id for each probe and each series. Then, we selected the
genomic factors with a consistent discriminative ability across the ﬁve
series, i.e. with an index value above a given threshold. For choosing
the threshold, we considered the intersection procedure ‘sdef’ [19].
The procedure was applied on the ﬁve lists ranked according to the
value of Id. It allowed us to determine the smallest threshold corre-
sponding to an association ratio (observed to expected) greater than 2
under the hypothesis of independence.
2.2.2. Results of the gene selection
The ‘sdef’ procedure led to a threshold of 8%. A total of 28 probe sets
were selected (see Table 1).
Among the genes selected, 10 are directly involved in the cell cycle
regulation (p-value = 9.3 × 10−6 when using Ingenuity Pathway Anal-
ysis on the selected genes): MKI67, APC, CENPF, PRDM5, CAST, HAUS5,
KDM5A, NDC80, NUSAP1 and xtitRACGAP1. None of the corresponding
probe sets was selected using the four indices ρn2, RN2, ρk2 and ρXOQ2 .
Gene MKI67 encodes a nuclear protein associated with cell cycle
activity, which is a key feature of the progression of tumors. MKI67 is
an independent prognostic factor for disease-free survival and provides
useful information for therapeutic decisions in breast cancer patients
[20]. Furthermore, it is one of the targets of the commercially available
multigene assays Oncotype DX and it is heavily weighted in the formula
used to calculate the Oncotype DX recurrence score [21].
Fig. 6 shows that high levels of MKI67 expression are associated
with bad prognosis. For some studies the survival curves converge
with time. Such convergence of the survival curves implies a violation
of the proportional hazards assumption.
The Adenomatous Polyposis Coli (APC) gene encodes a tumor sup-
pressor protein that acts as an antagonist of the Wnt signaling path-
way [22]. A germline defect of this gene causes familial adenomatous
Fig. 2. Simulation results for Id ρn2, RN2, ρk2 and ρXOQ2 for n = 200 subjects, G ~ (0,1), exp(−θ) = 0.50, pc = 0 (1000 repetitions).
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cers. In particular, the expression of APC is frequently altered by a dele-
tion on chromosome 5q in sporadic breast cancers.
Gene CENPF (centromere protein F) is involved in cell division. It
encodes a protein that associates with the centromere–kinetochore
complex. It plays a role in chromosome segregation during mitosis
and is a marker of tumor proliferation [23]. It is one of the 231 genes
found to be signiﬁcantly associatedwith disease outcome in the seminal
study of Van't Veer et al. [24]. In a recent work [25], O'Brien et al. vali-
dated the interest of this marker using two independent breast cancer
patient cohorts where CENPF protein expression was evaluated by
immuno-histochemistry. They showed that CENPF is correlated with
markers of aggressive tumor behavior including ER negativity and
high tumor grade. It has also been recently suggested that CENPF is a
potential newmolecular target for zoledronic acid (nitrogen-containing
bisphosphonate) in tumor cells [26].
Gene PRDM5 (PR domain containing 5) causes growth arrest
and apoptosis. Its expression is commonly silenced in several cancer
types examined, including breast cancer [27]. It acts as a tumor
growth suppressor.
The epigenetic modiﬁer gene KDM5A (lysine-speciﬁc demethylase
5A) encodes a lysine-speciﬁc histone demethylase, which regulates the
expression of multiple genes. A recent study shows that an increasedexpression ofKDM5A in breast tumors leads to global histonemethylation
level changes [28]. This alters the expression of key genes involved in the
apoptotic response, which have a potential role in drug resistance of
tumor cells. Targeting histone demethylase is nowadays an active frontier
in epigenetic drug development and KDM5A may represent a target for
the development of novel anticancer drugs that may work for various
patients.
Gene NDC80/HEC1, component of a kinetochore complex, is required
for kinetochore integrity, chromosome segregation and mitotic spindle
checkpoint. In a recent paper, the deregulation of NDC80/HEC1 is shown
to be involved early in breast carcinogenesis [29]. The authors of the
paper highlight its clinical relevance.
Gene RNASEH2A encodes the catalytic subunit of the RNase H2
heterotrimer and participates in DNA replication. A recent work con-
ﬁrms its over-expression in several cancer cell lines, including MCF7
breast cancer cell lines [30]. The authors of this work also show
that the inhibition of RNASEH2A leads to a reduction of the anchorage-
independent proliferation. From these results, the authors concluded
that RNASEH2A is a novel putative cancer drug target.
Gene RACGAP1 encodes a Rac GTPase-activating protein involved in
cell growth regulation andmetastasis. It has been recently reported that
a high level of expression of RACGAP1 is predictive for early cancer
recurrence [31,32].
Fig. 3. Simulation results for Id ρn2, RN2, ρk2 and ρXOQ2 for n = 200 subjects, G ~ (0,1), exp(−θ) = 0.50, pc = 0.25 (1000 repetitions).
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and plays a role in spindle formation [33]. An article shows that the
over-expression of NUSAP1 results in mitotic arrest in several human
cell lines, including MCF7 breast cancer cell lines [34].
3. Discussion
In cross-study survival analysis, the use of discrimination indices
based on the Cox PH model is a valuable approach for identifying
common prognostic markers. Combining survival analyses of clinical
series with heterogeneous populations and therapies allows to borrow
strength across them in order to select clinically relevant markers.
However, it relies on the assumption of proportional hazards, which
does not hold when the population under study is a mixture. Such
case is commonly encountered in early-stage cancer studies. In these
studies, the primary treatment is effective at eliminating the tumor
for a non-negligible proportion of patients (cured patients) whereas it
leads for the others (uncured patients) to a lower tumor burden
with various dynamic growths. For these uncured patients, the main
objective is to identify genomic markers able to characterize tumor
dynamic growth. A naive application of Cox model-based discrimina-
tion indices ignores the presence of non-susceptible patients andimpairs the ability to ﬁnd novel markers. The proposed discrimination
index is tackling this difﬁcult problem. It relies on a cure rate modeling
framework and quantiﬁes the ability of a marker to separate uncured
patients based on their time-to-event outcomes. It is an adjusted
discrimination index that takes into account the effects of potential
variables on the cure fraction.
As seen from the simulation study, our index showed good perfor-
mances for assessing tumor dynamic discrimination as compared to clas-
sical indices based on the Cox proportional hazards model. It increased
with the strength of effect and was neither affected by the sample size
nor the cure rate fraction. Simulation results also showed that the
index is insensitive to the effect of a variablemodifying the cure fraction,
which is not the case for the other indices.
The proposed index provides a measure of separability taken into
account the effect of variables on the cure fraction through a classical
multiplicative link. It can be easily extended for complex links by strat-
ifying the index based on the different levels of the covariates.
The use of this novel index for cross-study gene expression analyses
allowed to select markers with a prognostic consistency across various
heterogeneous groups of patients for any primary treatment and
clinical factors. In our breast cancer analysis, we have selected the
well-known gene MKI67 as well as other markers such as KDM5A,
Fig. 4. Survival curve of the ﬁve breast cancer studies. Dotted lines represent the 95% conﬁdence interval.
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drugs. None of the other PH-related discrimination indices selected
these genes.
Finally, we proposed a model-based discrimination index which
represents a novel tool tailored for cross-study analysis in early stage
cancer.
4. Material and methods: derivation of a discrimination index
In this work, the effect of the genomic marker on the dynamic of
tumor relapse among uncured patients is modeled by an improper
survival distribution. We ﬁrst present this semi-parametric cure rate
model [6] that belongs to the general class of bounded cumulative
hazards models (for a review of cure rate models, see [35,36]). Then,
we derive with the discrimination index. The index is based on the
score statistic deduced from the partial likelihood. It is interpreted in
terms of percentage of separability between uncured patients based
on their survival times and genomic marker measurements.
4.1. Notation and cure rate model
For each subject i, i ∈ {1,…,n}, let the random variables Xi and Ci be
the failure and censoring times which are assumed to satisfy the condi-
tion of independent censoring [37]. Let Ti = min(Xi,Ci) be the observed
follow-up time, δi ¼ 1 Xi¼Tið Þ the indicator of event andYi tð Þ ¼ 1 Xi≥tð Þ the
indicator of being at risk at time t. Let Zi be a covariate andGi the genomic
marker measurement for the subject i. For subject i, the data consist of
Xi, δi, Gi and Zi.
We consider the classical semi-parametric bounded cumulative haz-
ardsmodel, where the survival function of Ti given Zi and Gi is given by:
S t Zi;Gi

¼ exp −θ Zið Þ 1− exp −H tð Þe
γGi
 h in o ð1Þwhere H(t) is an unspeciﬁed continuous positive function increasing
from zero to inﬁnity, θ Zið Þ is a positive parameter that depends on Z
andγ is the parameter for the genomicmarkerG. The corresponding cu-
mulative hazards function Λ(t|Zi,Gi) = − log[S(t|Zi,Gi)] is bounded, in-
creases with t and reaches its maximum for θ Zið Þ. In this work, we
consider the general case where the covariate Z has a multiplicative ef-
fect on the cure fraction such as:θ Zið Þ ¼ θe
αZi whereα is anunknownpa-
rameter and θ is a positive parameter. If the series is homogeneouswith
the same cure fraction (i.e. α = 0), themodel reduces to the simple fol-
lowing expression: S t Gij Þ ¼ exp −θ 1−exp −H tð ÞeγGi
n o n o
.
Model (1) can be written in terms of the hazards function λ(t|Zi,
Gi) as follows:
λ

t Zi;Gij Þ ¼ θeαZi h tð ÞeγGi e−H tð Þe
γGi
where h tð Þ ¼ ∂H tð Þ∂t is an arbitrary baseline hazard function.
Parameter γ is the parameter of interest. It quantiﬁes the impact of
the genomic marker on the dynamic of cancer progression (for the
uncured patients). Parameters α and θ are considered as nuisance
parameters.
The partial likelihood is obtained as follows:
L t;γ;αð Þ ¼ ∏
n
i¼1
eαZi eγGi e−H tð Þe
γGi
∑nj¼1 Yj tið ÞeαZj eγGj e−H tð Þe
γGj
2
4
3
5δi :
We consider the null hypothesis H0 : γ ¼ 0;∀αf g, which refers to
the absence of impact of the genomic marker on the tumor growth
Fig. 5. Representation of the selection of genes common to different cancer studies. First, genes are ranked according to their pseudo-R2 values. Then, we count the number of genes
for which the index is greater than a given threshold value across the different datasets. Finally, we calculate the ratio between this latter number and the expected number of genes
in common under the hypothesis of independence between the experiments. The threshold is chosen such that the ratio between the two numbers was greater than 2.
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derive the ith element of the score function underℋ0 such as:
Vi ¼
∂ logL ti;γ;αð Þ
∂γ

γ¼0 ¼ δi 1þ log 1−Λ0 tið Þ=θf gð Þ Gi−
∑l∈Ri Gle
αZl
∑l∈Ri e
αZl
 !
whereℛi is the risk set at time ti.4.2. Discrimination index
In the following,we show that the quantityVi can be reformulated as
an index of separability that quantiﬁes the ability of a genomic factor to
separate patients who experience the event at time ti from those who
are still at risk (as illustrated in Fig. 1).Let w be a weighting function deﬁned as w Zið Þ ¼ eα^Zi. The score
function can be written as
Vi ¼ δi 1þ log 1−Λ0 tið Þ=θf gð Þ  Gi−
∑l∈Ri w Zlð ÞGl
∑l∈Ri w Zlð Þ
 !
Vi ¼ δi 1þ log 1−Λ0 tið Þ=θf gð Þ
∑l∈Ri w Zlð Þ
∑l∈Ri w Zlð Þ
 !
 Gi−
∑l∈Ri w Zlð ÞGl
∑l∈Ri w Zlð Þ
 !
Vi ¼ δi 1þ log 1−Λ0 tið Þ=θf gð Þ
∑l∈Ri w Zlð Þ
∑l∈Ri w Zlð Þ
 !
 Gi−Gwi
 
where Ri is the risk set without the individual that experienced the
event at time ti.
The score function Vi can be reinterpreted as a weighted difference
between (1) the mean value of the genomic marker for the individuals
who experience the event at ti and (2) the weighted mean for those
Table 1
Genes with a consistent effect on survival across the ﬁve studies, for Id ≥ 8%. Values in columns 5 to 9 indicate the percentage of separability calculated with the proposed index.
Probe set ID Gene symbol Gene title Chr. GSE11121
(n = 200)
GSE12093
(n = 136)
GSE16446
(n = 107)
GSE2034
(n = 286)
GSE9195
(n = 77)
200790_at ODC1 Ornithine decarboxylase 1 2p 9.68 17.52 9.07 12.80 11.61
201719_s_at EPB41L2 Erythrocyte membrane protein band 4.1-like 2 6q 9.85 23.79 8.82 10.18 23.02
201795_at LBR Lamin B receptor 1q 8.34 21.57 11.79 9.10 35.25
202028_s_at RPL38 Ribosomal protein L38 17q 34.59 8.78 15.18 9.35 25.89
202040_s_at KDM5A Lysine (K)-speciﬁc demethylase 5A 12p 10.78 8.83 11.92 11.45 12.47
202369_s_at TRAM2 Translocation associated membrane protein 2 6p 9.27 9.33 28.98 16.35 11.03
202613_at CTPS CTP synthase 1p 14.37 10.07 10.30 18.99 26.94
203022_at RNASEH2A Ribonuclease H2, subunit A 19p 30.57 10.47 11.31 9.28 44.41
204162_at NDC80 NDC80 homolog, kinetochore complex component (S. cerevisiae) 18p 28.39 27.15 23.29 17.54 12.01
206396_at SLC1A1 Solute carrier family 1 (neuronal/epithelial high afﬁnity glutamate
transporter, system Xag), member 1
9p 16.89 21.87 11.46 10.50 17.50
207828_s_at CENPF Centromere protein F, 350/400ka (mitosin) 1q 31.13 14.56 9.45 23.07 10.13
211991_s_at HLA-DPA1 Major histocompatibility complex, class II, DP alpha 1 6p 30.10 9.26 9.16 11.25 10.14
212022_s_at MKI67 Antigen identiﬁed by monoclonal antibody Ki-67 10q 24.64 8.14 9.34 11.61 10.51
212182_at NUDT4 Nudix (nucleoside diphosphate linked moiety X)-type motif 4 12q 8.61 19.29 21.04 19.05 8.88
212479_s_at RMND5A Required for meiotic nuclear division 5 homolog A (S. cerevisiae) 2p 14.26 18.68 17.33 13.60 9.18
212586_at CAST Calpastatin 5q 25.61 16.01 9.93 28.57 31.20
212692_s_at LRBA LPS-responsive vesicle trafﬁcking, beach and anchor containing 4q 11.03 9.34 11.84 15.02 10.71
213053_at HAUS5 HAUS augmin-like complex, subunit 5 19q 8.57 20.81 14.07 8.59 19.75
214603_at MAGEA2 Melanoma antigen family A, 2 Xq 17.31 26.16 40.18 8.56 15.23
216474_x_at TPSAB1 Tryptase alpha/beta 1 16p 37.71 11.61 22.18 13.02 8.54
216933_x_at APC Adenomatous polyposis coli 5q 10.91 10.72 26.23 8.90 9.02
217995_at SQRDL Sulﬁde quinone reductase-like (yeast) 15q 13.91 17.31 12.17 19.03 8.50
218218_at APPL2 Adaptor protein, phosphotyrosine interaction, PH domain and leucine
zipper containing 2
12q 24.11 15.61 14.04 9.82 8.69
219913_s_at CRNKL1 Crooked neck pre-mRNA splicing factor-like 1 (Drosophila) 20p 10.20 12.59 10.91 23.37 27.02
219978_s_at NUSAP1 Nucleolar and spindle associated protein 1 15q 28.97 21.95 18.04 24.30 9.41
220792_at PRDM5 PR domain containing 5 4q 9.21 19.49 12.82 10.47 43.43
220877_at – – – 9.01 20.77 31.75 10.64 15.16
222077_s_at RACGAP1 Rac GTPase activating protein 1 12q 36.07 39.68 8.09 11.78 11.62
Fig. 6. Survival curve according to the dichotomized level of expression of gene MKI67 for the ﬁve different breast cancer studies. The corresponding value of the pseudo-R2 is in-
dicated on each graph.
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close to zero indicate a weak or null separability. Large differences indi-
cate that the two groups are well separated.
Theweighting of the gene expression valuesGwi reﬂects themixture
of cured and uncured patients in the “at risk population”. The function
w(.) gives more weights to patients belonging to groups with a higher
fraction of uncured patients or with a lower fraction of cured patients,
see Fig. 1.
Hence, a global index over time can be computed as the sum of the
differences Vi such as
V ¼
Xn
i¼1
Vi ¼
Xn
i¼1
δi 1þ log 1−Λ0 tið Þ=θ½ f g
∑l∈Ri w Zlð Þ
∑l∈Ri w Zlð Þ
" # !
 Gi−Gwi
 
:
Since there are time-dependent changes in the composition of the
population (the fraction of uncured patients is progressively exhausted
as time goes on), the ﬁrst term gives more weight to earlier events.
Finally, the mean squared difference is: Δ0 = (∑i = 1n Vi)2/K2,
where K is the number of individuals having experience the event of
interest (i.e. not censored). This quantitymeasures the ability of a geno-
mic factor to separate uncured patients according to their time-to-event
outcome. The practical expression of Δ0 is obtained by replacing Λ0, θ
and α by their respective estimators Λ^ 0, θ^ and α^ . The cumulative hazard
functionΛ0(t) is estimated by the left-continuous version of theNelson–
Aalen function obtained using the pooled sample [38,39]. The cure
fraction θ is estimated by θ^ ¼ Λ^ 0 tmaxð Þ, where tmax is the last observed
failure time. Finally, α^ is the usual partial likelihood estimator under
the proportional hazardsmodel obtained by settingγ = 0 inmodel (1).
From previous results [5], we can deduce the theoretical maximum
value of Δ0 (noted Δmax) which corresponds to the case where γ
tends to inﬁnity, as follows:
Δmax ¼
Xn
i¼1
δi 1þ log 1−Λ^ 0 tið Þ=θ^
n o  Gi−∑l∈Ri Gleα^Zl
∑l∈Ri e
α^Zl
 !
−
Xn
l¼1
δl 1þ log 1−Λ^ 0 tlð g=θ^
n  
∑r∈Rl e
α^Zr
Gi−∑r∈Rl Gre
α^Zr
∑r∈Rl e
α^Zr
 !
8>>><
>>>:
9>>>=
>>>;
2
ð2Þ
Finally, we obtain the following tumor growth dynamic discrimi-
nation index (noted Id):
Id ¼
Δ0
Δmax
:
The index is unit-less, ranges from zero to one, increases with the
marker effect on tumor growth dynamic and is neither affected by the
sample size nor by the cure fraction.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.ygeno.2013.02.013.
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